VEGFA and cancer: Anti-Ang2 strategy was suggested as a potential 2nd-generation antiangiogenic cancer therapy, in view of the recognized limitations of anti-VEGF therapy.[12, 31]Actually, this kind of therapeutics has been actively tested in different clinical settings.[17, 31]Application of anti-Ang2 therapy in the postoperative adjuvant setting in preclinical models was shown to be promising.[12] The translation of these findings from bench to bedside, however, needs some prerequisite clinical data, among them is the perioperative dynamics of patient plasma Ang2.